Gonzalez R, Havrilesky LJ, Myers ER, Secord AA, et al. Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the
biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed
advanced stage ovarian cancer. Gynecol Oncol 2020 Aug 27. pii: S0090-8258(20)33759.
PMID: 32863036